Clinical Trials Logo

Filter by:
NCT ID: NCT06013761 Recruiting - Epilepsy Clinical Trials

IF-MCT 16:8: Investigating the Influence of Intermittent Fasting With and Without MCTs in Patients With Drug-resistant Epilepsy

IF-MCT16:8
Start date: July 25, 2023
Phase: N/A
Study type: Interventional

The objective of the prospective monocentric pilot trial is to investigate the influence of intermittent fasting with or without a once-daily intake with medium chain triglycerides (MCTs) on the frequency of seizures in patients with therapy-refractory epilepsy. The effects of 12 weeks intermittent fasting according to the 16:8 method (IF 16:8) are compared to 12 weeks intermittent fasting with additional intake of exogenous MCTs (IF MCT 16:8) in a within-subject-crossover-design in 28 patients with drug-resistant epilepsy.

NCT ID: NCT06012435 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Start date: February 21, 2024
Phase: Phase 3
Study type: Interventional

This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer that has spread through their body or can't be removed with surgery. Participants in this study must have been treated with no more than a platinum-based chemotherapy and an anti-PD-(L)1 drug. Participants with tumors that have certain treatable genomic alterations must have had at least 1 drug for that genomic alteration, in addition to platinum-based chemotherapy. This clinical trial uses an experimental drug called sigvotatug vedotin (SGN-B6A), which is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial also uses a drug called docetaxel. Docetaxel is an anticancer drug that has been approved to treat non-small cell lung cancer. It is usually given to patients who previously received another anticancer treatment. In this study, one group of participants will get sigvotatug vedotin on Days 1 and 15 during each 28-day-cycle. A second group of participants will get docetaxel on Day 1 during each 21-day cycle. This study is being done to see if sigvotatug vedotin works better than docetaxel to treat participants with NSCLC. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.

NCT ID: NCT06011642 Recruiting - Clinical trials for Psychological Disease

Reliability and Validity of a Digital Version of a Structured Interview for Children and Adolescents (Kinder-eDIPS)

Start date: December 3, 2021
Phase:
Study type: Observational

The Kinder-eDIPS is a digital version of the Kinder-DIPS (Diagnostisches Interview bei Psychischen Störungen im Kindes- und Jugendalter), a structured interview to assess a variety of the most frequent psychological disorders in children and adolescents. In this study, the reliability, validity and acceptance of the Kinder-eDIPS will be tested in both a clinical and a non-clinical sample.

NCT ID: NCT06011187 Recruiting - Outcome Clinical Trials

Assisted Fluid Management (AFM) System and Postoperative Outcome After High-risk Abdominal Surgery

PEFLA
Start date: February 1, 2024
Phase: N/A
Study type: Interventional

Goal directed fluid therapy (GDFT) or "Personalized fluid therapy" may benefit high-risk surgical patients but these strategies are infrequently implemented. It has also been shown that without any goal or protocol for fluid resuscitation, large inter- and intra-provider variability exist that have been correlated with poor patient outcomes. Recently, an "Assisted Fluid Management" (AFM) system has been developed to help ease some of the work associated with GDFT protocol implementation. The AFM system may help increase GDFT protocol adherence while leaving direction and guidance in the hands of the care providers. This artificial intelligence-based system can suggest administration of fluid boluses, analyse the hemodynamic effects of the bolus, and continually re-assess the patient for further fluid requirements. To date, there are no large outcome study using this AFM system. The primary objective of this trial is thus to evaluate the impact of this AFM system to guide fluid bolus administration on a composite of major postoperative complications in high-risk patients undergoing high-risk abdominal surgery.

NCT ID: NCT06008080 Recruiting - Aortic Stenosis Clinical Trials

Post-Market Clinical Follow Up Study With Navitor Valve

VISTA
Start date: September 29, 2023
Phase:
Study type: Observational

Evaluation of the safety and performance of the Navitor TAVI System in a Global Study

NCT ID: NCT06007170 Recruiting - Clinical trials for Bilateral Vocal Cord Paralysis

Performance of the SPIRION Laryngeal Pacemaker in BVFP Patients Without Glottal Enlargement

Start date: July 27, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical investigation is to learn about the use of a novel medical device, the SPIRION Laryngeal Pacemaker, in patients suffering from bilateral vocal fold paralysis (BVFP). The main questions it aims to answer are: - Is the use of the device safe? - Does the device improve the participants ability to take a breath? Participants will be implanted with the SPIRION Laryngeal Pacemaker and the development of their symptoms will be observed for the following 2 years.

NCT ID: NCT06007144 Recruiting - Clinical trials for Bilateral Vocal Cord Paralysis

Performance of the SPIRION Laryngeal Pacemaker in BVFP Patients With Single-sided Glottal Enlargement

Start date: August 18, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical investigation is to learn about the use of a novel medical device, the SPIRION Laryngeal Pacemaker, in patients suffering from bilateral vocal fold paralysis (BVFP) and who have had at least one related surgery on one of their vocal folds. The main questions it aims to answer are: - Is the use of the device safe? - Does the device improve the participants ability to take a breath? Participants will be implanted with the SPIRION Laryngeal Pacemaker and the development of their symptoms will be observed for the following 2 years.

NCT ID: NCT06006754 Recruiting - Clinical trials for Acute Myocardial Infarction

Influence of Enteral Microbiome on Mortality of Patients With Cardiogenic Shock

Start date: August 30, 2023
Phase:
Study type: Observational

Cardiogenic shock is associated with a high mortality. The microbiome is a double-edged sword which can convey protective and detrimental cardiovascular effects. The significance of the enteral micobiome on cardiovascular mortality of patients with cardiogenic shock is still not known. This study aims to provide a deeper understanding of the role of the enteral microbiome and microbiome dependent metabolites in mortality and disease progression of patients with cardiogenic shock.

NCT ID: NCT06005246 Recruiting - Clinical trials for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (ICD-10 G93.3)

Munich ME/CFS Cohort Study

MUC-CFS
Start date: January 22, 2019
Phase:
Study type: Observational

The Munich cohort study MUC-CFS aims at the characterization and long-term follow-up of myalgic encephalitis/chronic fatigue syndrome (ME/CFS) in young people aged up to 25 years, as well as at the identification of pathomechanisms, biomarkers, and targets for future treatment approaches.

NCT ID: NCT06004531 Recruiting - Anxiety Clinical Trials

Planetary Health and Loneliness

PAL
Start date: August 28, 2023
Phase: N/A
Study type: Interventional

The aim of this online study is the evaluation of planetary health behaviors in relation to levels of eco-anxiety, general well-being, and levels of loneliness. As climate change progresses at a dangerous rate, it is important to establish and maintain lifestyles that are productive, fulfilling, environmentally conscious, and low in anxiety. Through a better understanding of the interconnected nature of planetary health behaviors with other aspects of healthy living and perception of social isolation, this study will add to current state of science to help inform the creation of interventions promoting sustainable, healthy, happy living among the general public and specific subgroups.